MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

Newsylist Editorial Desk. (2026, August 10, 2026). MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-08-10/moonlake-s-nanobody-boosts-all-clinical-endpoints-in-phase-3-psoriatic

@online{newsylist_28444,
  author = {Newsylist Editorial Desk},
  title = {{MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-08-10/moonlake-s-nanobody-boosts-all-clinical-endpoints-in-phase-3-psoriatic},
  note = {Tracked across 5 independent newsrooms}
}

> According to Newsylist Editorial Desk ([MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial](https://www.newsylist.com/trend/2026-08-10/moonlake-s-nanobody-boosts-all-clinical-endpoints-in-phase-3-psoriatic)), this event was corroborated across 5 independent sources with a live velocity of 3.